Juvenescence is a life sciences company developing therapies to modify aging and increase healthy human lifespan. The Juvenescence team consists of highly experienced drug developers, entrepreneurs, marketers, and investors with a significant history of success in pharmaceutical drug development, synthetic biology, and tissue and cellular engineering. Juvenescence has a broad pipeline in development and is driving innovation, with a focus on discovering and developing these therapies to modify the aging process, through prevention and by regenerating damage, to support healthy aging and increase health span.
External link for Juvenescence®
88 Harcourt Street
Dublin, County Dublin D02, IE
Craigmuir Chambers, PO Box 71
Road Town, Tortola VG1110, VG
A fantastic several days filled with insightful discussions & presentations on prevention at the M42 Health Main Stage at Abu Dhabi Global Healthcare Week #ADGHW #FutureofHealthcare #AcceleratingtheFutureOfGlobalHealthcare
Juvenescence is proud to be sponsoring and presenting next week at Abu Dhabi Global Healthcare Week 13th-15th May. Join us at the M42 Health main stage to hear Jim Mellon & Richard Marshall CBE discuss innovation in the space among a great lineup of fascinating speakers brought together by The Longevity Forum and M42 Health! #AbuDhabiGlobalHealthcareWeek #ADGHW #AbuDhabi #LongevityForum #HealthyAging
First patient dosed! We are pleased to support LyGenesis in their mission to tilt the organ supply-demand imbalance in favor of patients. https://lnkd.in/ehwx7D2p
LyGenesis Announces First Patient Dosed in its Phase 2a Clinical Trial of a First-in-Class Regenerative Cell Therapy for Patients with End-Stage Liver Disease Michael Hufford Eric Lagasse #liver #clinicaltrial #ESLD #regenerativemedicine #lymphnodes https://lnkd.in/eKkRpKup
Juvenescence is pleased to support Chrysea's acquisition of Rodon Biologics, enhancing development capacities and accelerating commercialization #longevity #aging #biotech #biotechnology #syntheticbiology #Juvenescence #Chrysea #rodonbiologics https://lnkd.in/eKFXuKEb
Latest press release: Chrysea, led by Pedro de Noronha Pissarra, has partnered with Chalmers University of Technology to develop Benzylisoquinoline Alkaloids for Human and Animal Healthcare
Our co-founder Jim Mellon participated in ‘The Search for a Longevity Pill’ panel at the 2024 GlobalAlts24 conference. Here are our key takeaways: 🌍 The sector needs more money as ageing demographics are a global economic timebomb 🧬 The huge success of GLP1 agonist therapeutics is an example of what to expect for the potential for truly 'anti-ageing' therapeutics 🔬 ...and watch this space as Juvenescence therapies head towards the clinic...
Our CEO Richard Marshall CBE , CSO Gill Dines and head of Clinical development Steve Felstead visiting the Buck Institute for Research on Aging this week to discuss current and future research collaborations. Juvenesence is delighted to have a number of exciting programmes in partnership with the Buck heading into clinical development.
Great to spend time with our partners and friends at the Buck Institute for Research on Aging this week! My thanks to Eric Verdin Remy Gross, Rosalba Perrone , Ph.D and Prasanna Vadhana Ashok Kumaar for hosting us. Thanks also to the great PIs who gave up their time to update us on the incredible work they’re doing to understand mechanisms of #healthspan #longevity
Juvenescence® reposted this
The longevity cities panel at Milken Institute featuring Rajiv Ahuja, JD Jim Mellon of Juvenescence® , Tina Woods of Collider Health and Sergey Young of the Longevity Vision Fund 💡 Very well attended! "We are the first cohort to benefit from the fundamental advances of geroscience" - Jim Mellon.
Juvenescence® reposted this
Our CEO Dr. Richard Marshall CBE shared his insights on Pharmaceuticals for Healthspan at The Longevity Forum's Longevity Week 2023. We'd love to hear your insights from this year's event 💡
Our CEO Dr. Richard Marshall CBE shared his insights on Pharmaceuticals for Healthspan at The Longevity Forum's Longevity Week 2023. We'd love to hear your insights from this year's event 💡